When Should I See a Cardiologist for High Cholesterol?

Most people with high cholesterol never need to see a cardiologist. A primary care doctor can diagnose the problem, prescribe a statin, and monitor your levels over time. The situations that do call for a cardiology referral tend to be specific: an LDL level that stays stubbornly above 190 mg/dL, a suspected genetic lipid disorder, trouble tolerating standard medications, or existing cardiovascular disease that demands aggressive treatment. Understanding where those lines fall can save you both unnecessary specialist visits and dangerous delays.

When Your Primary Care Doctor Is Enough

For the vast majority of adults whose cholesterol is mildly to moderately elevated, the family doctor or internist is the right person to manage the condition. Lifestyle counseling, statin prescriptions, and routine bloodwork all fall squarely within primary care. Even among people diagnosed with familial hypercholesterolemia, one of the more serious genetic lipid conditions, only a small proportion actually require specialist management; the majority can be treated in primary care once the diagnosis is established and a treatment plan is set.¹ Your doctor will typically start with a standard lipid panel, calculate your overall cardiovascular risk based on age, blood pressure, smoking status, and diabetes, and decide whether medication is warranted.

A referral makes sense when the situation moves beyond what standard tools can handle. Think of it this way: if your cholesterol responds to a statin, your risk factors are under control, and your LDL drops to a reasonable level, there is no clinical reason to involve a cardiologist. The triggers for referral are about complexity, resistance, or high stakes.

The LDL 190 Threshold

One of the clearest triggers for escalated care is an LDL cholesterol level at or above 190 mg/dL. Current guidelines from the American College of Cardiology and the American Heart Association recommend high-intensity statin therapy for anyone age 20 or older with an LDL that high, without even bothering to calculate a 10-year cardiovascular risk score, because the long-term danger is assumed to be elevated enough on its own.² A primary care doctor can and should start that statin. But if three to six months of maximum-dose statin therapy fails to bring LDL down by at least half, or if the level suggests an underlying genetic cause, a referral to a lipid specialist or cardiologist is the logical next step.

An LDL persistently above 190 also raises suspicion for familial hypercholesterolemia, which requires a different level of attention and often different medications. Your primary care doctor may flag this possibility, but confirming it and mapping out a long-term treatment strategy tends to involve a specialist.

Familial Hypercholesterolemia

Familial hypercholesterolemia, or FH, is one of the most common inherited disorders you have probably never heard of. It affects roughly 1 in 500 people and causes high cholesterol from birth, yet fewer than 15% of those affected are currently seen at lipid clinics, meaning the vast majority go unrecognized in general practice.³ The clue is usually a family history of premature heart disease, meaning heart attacks or coronary procedures in male relatives under 55 or female relatives under 65, combined with LDL levels well above 190 mg/dL.

If your doctor suspects FH, a cardiologist or lipid specialist can confirm the diagnosis, arrange genetic testing, and start what is sometimes called “cascade screening,” which means testing your close relatives to catch other affected family members early. The treatment goal for people with FH is aggressive: at least a 50% reduction in LDL from baseline, and often much more.⁴ Reaching that target frequently requires medications beyond statins, which is where specialist involvement becomes essential.

When Statins Are Not Working or Not Tolerated

Statins are the backbone of cholesterol treatment, but they do not work perfectly for everyone. At least 5% of people taking statins develop muscle symptoms, which can range from mild aches to severe pain that makes daily life difficult.⁵ Observational studies and registries report even higher rates, somewhere between 7% and 29%, depending on how broadly muscle complaints are defined.⁶ The good news is that more than 90% of people with statin-related muscle problems can keep taking a statin long term after switching to a different type, adjusting the dose, or changing how often they take it.⁵

Your primary care doctor can usually handle the first round of troubleshooting: trying a lower dose, switching from one statin to another, or adding a non-statin drug like ezetimibe. Where a cardiologist or preventive cardiologist becomes valuable is when you have cycled through multiple statins without success, when your LDL remains far above target despite these adjustments, or when the muscle symptoms are severe enough to raise concern about a rarer complication called statin-associated myopathy, which involves measurable muscle damage and affects roughly 1 in 1,000 to 1 in 10,000 people on standard doses.⁶

Advanced Medications That Usually Involve a Specialist

Some of the newer cholesterol-lowering drugs sit firmly in specialist territory, not because primary care doctors cannot prescribe them but because insurance companies and clinical norms have placed them there. PCSK9 inhibitors, a class of injectable medications, can lower LDL by roughly 50% to 60% on top of whatever a statin is already doing.⁷ Surveys of clinicians in the U.S. have found that both general and preventive cardiologists are the preferred specialties for prescribing PCSK9 inhibitors and related agents, while primary care doctors are the default for statins and ezetimibe.⁸

A newer option, inclisiran, works differently. It is an injectable given just twice a year by a healthcare provider, which could help with the common problem of patients forgetting or stopping medications. In trials, a two-dose regimen of inclisiran at 300 mg reduced LDL by about 53% from baseline at six months, and nearly half of patients on that regimen reached an LDL below 50 mg/dL.⁹ However, the long-term cardiovascular outcomes data for inclisiran are still being collected, so its role relative to the existing PCSK9 monoclonal antibodies is still settling.¹⁰ If your doctor mentions any of these drugs, you are likely heading for a cardiology or lipid clinic referral, if you are not there already.

After a Heart Attack or Procedure

If you have already had a cardiovascular event, such as a heart attack, a stent placement, or bypass surgery, the cholesterol conversation changes completely. You are now in “secondary prevention,” and the targets are stricter. Guidelines recommend getting LDL below 70 mg/dL, and in very high-risk patients, even lower. If maximum-dose statin therapy does not get you there, ezetimibe is typically added first, followed by a PCSK9 inhibitor if needed.¹¹ In patients who underwent coronary stenting and had an LDL at or above 55 mg/dL, achieving at least a 50% reduction in LDL was associated with a significant drop in major adverse cardiac events.¹²

In practical terms, if you have had a heart event, you are almost certainly already seeing a cardiologist. The cholesterol management becomes part of that ongoing relationship rather than a separate referral question. The more relevant issue is making sure cholesterol is being managed aggressively enough. If your cardiologist is not discussing your LDL target and whether you are meeting it, bring it up.

Lipoprotein(a) and Hidden Cardiovascular Risk

Standard lipid panels measure LDL, HDL, and triglycerides. What they do not measure is lipoprotein(a), often written as Lp(a), a genetically determined particle that raises cardiovascular risk independently of your LDL level. You can have a perfectly controlled LDL and still face elevated risk if your Lp(a) is high.¹³ In a large multi-ethnic U.S. cohort, people with Lp(a) levels at or above the 90th percentile had roughly a 46% higher risk of cardiovascular events compared to those below the 50th percentile, and the association was even stronger in people with diabetes.¹⁴

Lp(a) levels are largely determined by your genetics and do not respond to lifestyle changes or statins the way LDL does. The concentrations vary enormously between individuals, from less than 1 mg/dL to over 1,000 mg/dL.¹³ Genetic studies suggest the association between elevated Lp(a) and premature heart disease is causal, not just correlational.¹⁵ If you have a strong family history of early heart disease and your LDL looks fine, asking for an Lp(a) test is reasonable. A high result is another reason to see a cardiologist, especially since the advanced lipid testing and therapeutic options that follow are typically managed by specialists. No approved Lp(a)-lowering drug is widely available yet, but several are in late-stage clinical trials, and specialist guidance on overall risk reduction is valuable in the meantime.

Rule Out Thyroid Problems and Other Secondary Causes First

Before assuming your high cholesterol is a cardiology problem, it is worth making sure something else is not driving it. Hypothyroidism, where the thyroid gland is underactive, is the most common secondary cause of elevated cholesterol after diet.¹⁶ An underactive thyroid slows the body’s ability to clear LDL from the blood, so cholesterol climbs for reasons that have nothing to do with your arteries. In these cases, treating the thyroid problem with replacement hormone often improves the lipid profile on its own.¹⁷

Other conditions that can raise cholesterol include kidney disease, liver disease, and certain medications. A thyroid function test (TSH and thyroxine levels) should be part of the workup for anyone presenting with new, clinically significant high cholesterol.¹⁶ Your primary care doctor should be running these tests before you ever need to think about a cardiologist. If a secondary cause is found and treated but cholesterol remains elevated, then the question of specialist referral comes back on the table.

Coronary Artery Calcium Scoring

For people in a gray zone, where the cholesterol is elevated but overall cardiovascular risk is borderline, a coronary artery calcium (CAC) scan can help clarify the picture. This is a low-dose CT scan that detects calcium deposits in the coronary arteries, a marker of plaque buildup. International guidelines endorse the CAC score as a decision aid in primary prevention, and a score of zero, sometimes called the “power of zero,” can be used to reassure patients and their doctors that it may be safe to delay or avoid starting a statin.¹⁸

A CAC scan is usually ordered by a cardiologist or preventive cardiologist, though some primary care physicians order them too. The scan itself is quick, painless, and does not require contrast dye. If your score comes back elevated, you and your doctor have harder evidence that treatment is warranted. If it comes back zero and your LDL is only moderately elevated, the conversation may shift toward lifestyle changes with follow-up testing down the road. The scan does not replace a lipid panel; it adds context to one.

Cholesterol Management During Pregnancy

Pregnancy creates a unique cholesterol dilemma. Cholesterol naturally rises during pregnancy because the body needs it for fetal development. At the same time, statins have traditionally been contraindicated during pregnancy due to concerns about birth defects. A recent meta-analysis found no significant increase in major congenital anomalies in statin-exposed pregnancies when adjusted results were considered, but it did find a lower rate of live births and a higher rate of spontaneous miscarriages in the statin-exposed group.¹⁹ That means the standard advice remains to stop statins before or during pregnancy.

For women with familial hypercholesterolemia or very high LDL who are planning a pregnancy, this creates a gap in treatment that needs careful management. A cardiologist or maternal-fetal medicine specialist with lipid expertise can help weigh the risks, discuss which medications can safely be used during pregnancy, and plan the timeline for stopping and restarting statins. This is one of those situations where specialist input genuinely changes outcomes, because getting the timing wrong in either direction carries real consequences.

Insurance Barriers to Advanced Cholesterol Drugs

Even when a cardiologist decides you need a PCSK9 inhibitor, getting your insurance to pay for it can be a separate battle. Between 82% and 97% of privately and publicly insured individuals in the U.S. are enrolled in plans that require prior authorization for PCSK9 inhibitors, and a third to two-thirds of those plans restrict prescribing to a specialist.²⁰ For patients with familial hypercholesterolemia, many payers also require confirmation through genetic testing or clinical scoring criteria before approving the medication.

The administrative burden is substantial. Prior authorization forms often run multiple pages, and with more than ten thousand health plans in the U.S., the requirements vary widely between payers, with differing definitions of terms and criteria.²¹ High rejection rates are common, which means delays in treatment for people whose cardiovascular risk is already significant. One practical advantage of seeing a cardiologist or lipid specialist is that their offices tend to be more experienced with these authorization processes and more familiar with what documentation each insurer requires. That expertise can be the difference between getting the drug approved or waiting months through appeals.

Lipoprotein Apheresis for Extreme Cases

At the far end of the severity spectrum, some patients need a procedure called lipoprotein apheresis, which is essentially a dialysis-like process for filtering harmful lipoproteins out of the blood. The FDA supports apheresis for patients who have not responded adequately to six months of maximum diet and drug therapy, including those with homozygous FH and an LDL above 500 mg/dL, heterozygous FH with LDL above 300 mg/dL without coronary disease, or heterozygous FH with LDL above 200 mg/dL with documented coronary disease.²² It can also be used to lower Lp(a) in patients where that particle is driving cardiovascular risk.²³

Apheresis is performed every one to two weeks and requires a specialized center, which means it is exclusively managed by cardiologists and lipid specialists. It remains underused despite being effective, partly because of limited awareness and partly because relatively few centers offer it. If you or a family member has been diagnosed with severe FH and medications alone are not controlling the cholesterol, asking about apheresis is worthwhile. It is one of those treatments that many patients who qualify for never hear about.

What a Preventive Cardiologist Actually Does

If you are referred for cholesterol, you may end up seeing not a general cardiologist but a preventive cardiologist, a subspecialty focused specifically on stopping cardiovascular disease before it starts. Preventive cardiology grew out of the realization that lipid clinics, hypertension clinics, and diabetes clinics were often treating overlapping problems in isolation, and patients fell through the gaps between them. A dedicated preventive cardiology practice can integrate all of these risk factors in one place, coordinating care that is hard to replicate across separate specialty visits.

In practice, a preventive cardiologist will dig deeper into your risk profile than a standard visit allows. That might include advanced lipid testing that goes beyond the standard panel, looking at particle size and number rather than just total concentrations, to give a more precise picture of your actual risk.²⁴ It might include ordering a CAC scan, testing for Lp(a), screening family members, or navigating the insurance process for advanced medications. Not every patient with high cholesterol needs this level of attention, but for those who do, it is a different experience from a five-minute statin conversation in a busy primary care office.

1
PubMed. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services
2
PubMed Central. The evaluation and management of patients with LDL-C ≥ 190 mg/dL in a large health care system
3
PubMed Central. Identification and management of familial hypercholesterolaemia: what does it mean to primary care?
4
ScienceDirect. Executive Summary Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
5
PubMed Central. Treatment Options for Statin-Associated Muscle Symptoms
6
European Heart Journal. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
7
PubMed Central. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
8
Postgraduate Medical Journal. Specialty preference for cardiovascular prevention practice in the Southeast US and role of a preventive cardiologist
9
PubMed. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
10
PubMed Central. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
11
PubMed Central. Management of LDL-cholesterol after an acute coronary syndrome
12
The American Journal of Cardiology. Clinical Impact of Low-Density Lipoprotein Cholesterol Reduction Strategies in Patients Who Underwent Percutaneous Coronary Intervention
13
PubMed Central. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives
14
PubMed. Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort
15
European Heart Journal. Lipoprotein(a) as a cardiovascular risk factor: current status
16
PubMed. Secondary causes of hyperlipidemia
17
PubMed Central. Effects of thyroid dysfunction on lipid profile
18
BMJ. Role of coronary artery calcium score in the primary prevention of cardiovascular disease
19
PubMed Central. Dyslipidaemia management in pregnant patients: a 2024 update
20
PubMed. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
21
PubMed Central. PCSK9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing
22
PubMed Central. Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
23
PubMed. Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice
24
PubMed Central. Assessing Atherosclerotic Cardiovascular Disease Risk with Advanced Lipid Testing: State of the Science